Welcome to our dedicated page for ARYA Sciences Acquisition IV news (Ticker: ARYD), a resource for investors and traders seeking the latest updates and insights on ARYA Sciences Acquisition IV stock.
This page contains historical news coverage for Arya Sciences Acquisition Corp IV (ARYD), a Special Purpose Acquisition Company that focused on healthcare and life sciences mergers. The company completed its business combination with Adagio Medical and no longer operates under the ARYD ticker symbol. This archive provides context on the SPAC's formation, target search process, and the events leading to its merger completion.
The news archive documents key milestones including the SPAC's initial public offering, the announcement of its merger agreement with Adagio Medical, and the final completion of the business combination. These historical articles offer insight into how SPACs identify and negotiate with target companies, the regulatory approval process, and the transition to a combined operating entity. Investors researching the original SPAC structure or tracking their historical investment can review how the transaction unfolded.
For current news about the operating business that resulted from this merger, search for Adagio Medical's new ticker symbol. This ARYD news archive serves as a historical record of the SPAC phase before the business combination closed.
Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leader in catheter ablation technologies for cardiac arrhythmias, has provided a business update highlighting significant milestones. The company has obtained CE Mark approval and initiated the commercial launch of its vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for ventricular tachycardia (VT) treatment in Europe. Additionally, Adagio has received FDA approval for the FULCRUM-VT Pivotal IDE study in the US, with patient enrollment expected to begin in September.
The company recently closed a business combination with ARYA Sciences Acquisition Corp IV, resulting in its listing on the Nasdaq Capital Market under the ticker symbol 'ADGM'. This transaction, along with concurrent financings, raised approximately $84.2 million, leaving the company with a proforma cash-on-hand of about $35 million after closing.
Adagio Medical has completed its business combination with ARYA Sciences Acquisition Corp IV, creating a publicly traded company focused on innovative technologies for treating cardiac arrhythmias. The combined company, Adagio Medical Holdings, Inc., will trade on the Nasdaq Capital Market under the ticker symbol 'ADGM' starting August 1, 2024.
The transaction, approved by shareholders, raised approximately $84.2 million in financing. This includes funds from ARYA IV's trust account, a private placement led by investors like Perceptive Advisors and RA Capital Management, and convertible security financing.
Adagio Medical's focus will be on commercializing the vCLAS™ ultra-low temperature cryoablation (ULTC) catheter for treating ventricular tachycardia in Europe and executing the FULCRUM-VT Pivotal IDE trial recently approved by the FDA.
ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) has mutually terminated its Business Combination Agreement with Amicus Therapeutics, effective immediately, due to unfavorable market conditions. Despite this setback, ARYA IV has over a year to pursue a new business combination that aligns with its investment criteria. ARYA IV's dissolution deadline is set for March 2, 2023, unless extended. No termination fees will be incurred by either party. ARYA IV remains focused on delivering value for its shareholders.
ARYA Sciences Acquisition Corp IV has priced its initial public offering of 13,000,000 Class A ordinary shares at $10.00 each, to be traded under the ticker symbol ARYD on Nasdaq starting February 26, 2021. The company intends to focus on the healthcare sector, targeting businesses valued at $300 to $500 million, aiming for a market cap of $1 billion or more. The offering includes an option for underwriters to purchase an additional 1,950,000 shares. The expected closing date is March 2, 2021, subject to customary conditions.
FAQ
What is the current stock price of ARYA Sciences Acquisition IV (ARYD)?
What is the market cap of ARYA Sciences Acquisition IV (ARYD)?
